Shardul Amarchand Mangaldas (SAM), Linklaters, and JSA advised on Biocon’s ₹4,500 Crore (~USD 460 Million) Qualified Institutional Placement (QIP).

Biocon Limited has successfully completed a Qualified Institutional Placement (QIP) aggregating to approximately USD 460 million (₹4,500 crore).

The QIP was undertaken as part of Biocon’s strategy to fully integrate its subsidiary, Biocon Biologics, by combining businesses, and attracted participation from leading institutional investors.

Shardul Amarchand Mangaldas advised Biocon Limited on its Qualified Institutional Placement.

The capital markets team was led by Partner Prashant Gupta (National Practice Head – Capital Markets), along with Partner Ruth Chenchiah, and included Senior Associate Debolina Mitra and Associates Kunika Agarwal and Dipti Tharwani.

Linklaters Singapore acted as international counsel to the book running lead managers on the QIP. The Linklaters team was led by Partner Amit Singh (Head of the India Practice and Head – South and South East Asia Capital Markets).

JSA Advocates & Solicitors (JSA) advised Kotak Mahindra Capital Company Limited, HSBC Securities and Capital Markets (India) Private Limited, J.P. and Morgan India Private Limited, Morgan Stanley India Company Private Limited in relation to the Qualified Institutional Placement of equity shares of Biocon Limited of 112,664,585 equity shares of face value of ₹ 5 each aggregating to ₹ 41,500 million.

The JSA Capital Markets team was led by Lead Partner Madhurima Mukherjee Saha, with support from Partner Sagar Batra, Senior Associate Bhavini Mohan, and Associates Rachit Munjal, Nidhi Prakriti, Shivani Agrawal, Aryaman Singh & Kumar Shubham.